Zentalis Pharmaceuticals develops azenosertib, an experimental oral cancer drug for ovarian cancer and other tumors. It last closed at $1.36 on Nov 20, up 0.00% on the day. The next earnings report for ZNTL is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, ZNTL reported EPS of -$0.34. Over its last 8 reports the stock moved an average of 7.4% the session after earnings. Over the last 12 months ZNTL insiders bought $22.9M of stock on the open market and sold $10.1M, according to SEC Form 4 filings.
AI Auto Pilots
Is ZNTL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZNTL.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ZNTLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ZNTL · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 28% below its 20 day and 69% below its 50 day average. It is 148% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $1.29, and the nearest resistance the Pivot at $1.40.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.2%/day
Key levels
$6.9552 week high+411.0%
$3.37200 day average+147.8%
$3.30100 day average+142.6%
$2.3050 day average+69.1%
$1.98Swing high (Nov 11)+45.6%
$1.7420 day average+27.9%
$1.46Pivot R1+7.4%
$1.40Pivot+2.9%
$1.36Last close
$1.29Pivot S1−5.1%
$1.2852 week low−5.9%
Indicators
RSI (14)
23.93
Oversold below 30
Oversold
MACD
-0.27
Below its signal line
Bearish
Stochastic
5.8
Near the bottom of its range
Oversold
ADX (14)
49.0
Strong downtrend
Williams %R
-91.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-147.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.9%
Change over 10 sessions
Bearish
ATR (14)
$0.18
Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 43.3%/day
Key levels
$6.9552 week high+411.0%
$3.37200 day average+147.8%
$3.30100 day average+142.6%
$2.3050 day average+69.1%
$1.98Swing high (Nov 11)+45.6%
$1.7420 day average+27.9%
$1.46Pivot R1+7.4%
$1.40Pivot+2.9%
$1.36Last close
$1.29Pivot S1−5.1%
$1.2852 week low−5.9%
Indicators
RSI (14)
31.45
Weak, oversold below 30
Neutral
MACD
-0.53
Below its signal line
Bearish
Stochastic
2.4
Near the bottom of its range
Oversold
ADX (14)
26.3
Trending down
Williams %R
-97.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-121.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−61.3%
Change over 10 sessions
Bearish
ATR (14)
$0.59
Typical daily range, 43.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZNTL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ZNTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ZNTL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ZNTLHow many large options trades hit ZNTL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ZNTL in the last 90 days.
From SEC Form 4 filings by ZNTL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZNTL is in one of them and how their past ZNTL trades turned out.
Zentalis Pharmaceuticals is a drug developer based in San Diego, California. Its main focus is azenosertib, an experimental oral medicine that works by blocking a cell protein called WEE1. The drug is being developed for patients with ovarian cancer and possibly other tumor types. The company is testing it in clinical trials, with its current focus on patients with platinum-resistant ovarian cancer whose tumors show high levels of Cyclin E1 protein.